Axsome Therapeutics Resolves All SUNOSI Patent Litigation, Securing U.S. Market Exclusivity Through 2040
核心洞察
Axsome Therapeutics has settled all outstanding patent litigation related to its wake-promoting therapy SUNOSI (solriamfetol) with the last remaining first-to-file generic applicant.
Under the settlement, five generic companies may begin selling generic versions of SUNOSI starting on or after March 1, 2040, or September 1, 2040 if pediatric exclusivity is granted.
The resolution eliminates all legal uncertainty surrounding SUNOSI's intellectual property and provides Axsome with long-term revenue visibility for the product.
Axsome Therapeutics announced on June 3, 2026 that it has resolved all patent litigation related to its wake-promoting therapy SUNOSI (solriamfetol), effectively securing a lengthy period of market exclusivity in the United States. The litigations stemmed from Abbreviated New Drug Applications (ANDAs) filed by companies seeking FDA approval to market generic versions of SUNOSI.
The settlement was reached with the only remaining first-to-file generic applicant with pending patent litigation related to SUNOSI, bringing an end to all outstanding intellectual property disputes concerning the product.
Settlement Terms and Generic Entry Timeline
Under the terms of the agreement, Axsome will grant five companies the right to sell generic versions of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted. These entry dates are subject to FDA approval and conditions and exceptions customary for agreements of this type.
With this settlement, no other patent litigation relating to SUNOSI remains pending. As required by law, Axsome will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
Strategic Implications for Axsome's CNS Portfolio
The resolution removes ongoing legal uncertainty around one of Axsome's commercial central nervous system (CNS) assets. By eliminating all remaining patent disputes and locking in a defined entry point for generics, the deal clarifies Axsome's long-term revenue visibility from SUNOSI.
SUNOSI (solriamfetol) is indicated for excessive daytime sleepiness associated with narcolepsy (搜索) and obstructive sleep apnea (搜索). It forms part of Axsome's industry-leading neuroscience portfolio, which also includes FDA-approved treatments for major depressive disorder (搜索), agitation associated with dementia due to Alzheimer's disease (搜索), and migraine (搜索).
Axsome Therapeutics is a biopharmaceutical company focused on developing differentiated products with novel mechanisms of action for CNS conditions. The company states that its portfolio addresses a broad range of serious neurological and psychiatric conditions impacting over 150 million people in the United States.